Pantginis Reiterates Buy on ENV-105’s Emerging Resistance-Reversal Profile and Bayer Collaboration; Price Target Maintained at $12
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Kairos Pharma with a $12 price target. The recommendation is based on ENV-105's emerging resistance-reversal profile, positive Phase 1 safety data when combined with Tagrisso for NSCLC, and a strategic collaboration with Bayer for prostate cancer potential.
Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Kairos Pharma, Ltd.. The associated price target remains the same with $12.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Joseph Pantginis has given his Buy rating due to a combination of factors tied to ENV-105’s emerging profile and strategic positioning. The initial safety findings from the Phase 1 trial combining ENV-105 with Tagrisso in EGFR-mutant NSCLC show no serious toxicities attributed to ENV-105, supporting continued dose escalation toward a Phase 2 dose and preserving the opportunity to demonstrate clinical benefit.
At the same time, ENV-105 is being developed as a resistance-reversing add-on to Tagrisso rather than a direct rival, aiming to extend the durability of a multibillion-dollar standard-of-care therapy in a setting with limited post-progression options. Mechanistic support from other tumor types, the Bayer collaboration expanding prostate cancer potential, and the unchanged $12 price target collectively underpin Pantginis’s positive risk-reward view despite the current lack of NSCLC efficacy data.
Joseph Pantginis has given his Buy rating due to a combination of factors tied to ENV-105’s emerging profile and strategic positioning. The initial safety findings from the Phase 1 trial combining ENV-105 with Tagrisso in EGFR-mutant NSCLC show no serious toxicities attributed to ENV-105, supporting continued dose escalation toward a Phase 2 dose and preserving the opportunity to demonstrate clinical benefit.
At the same time, ENV-105 is being developed as a resistance-reversing add-on to Tagrisso rather than a direct rival, aiming to extend the durability of a multibillion-dollar standard-of-care therapy in a setting with limited post-progression options. Mechanistic support from other tumor types, the Bayer collaboration expanding prostate cancer potential, and the unchanged $12 price target collectively underpin Pantginis’s positive risk-reward view despite the current lack of NSCLC efficacy data.